No need to login to view prices!
|Create new account|
The BIOKÉ webshop is closed until January 2nd, 2019. We wish you a successful 2019!
Every year BIOKÉ speaks at professional seminars and comes to world wide exhibitions in the life science industry.
Are you eager to meet us? On the left sidebar our events calendar is shown, hope to see you next time!
The COVID-19 public health crisis affects everyone in our global community, and many scientists are working very hard to gain more knowledge about the SARS-CoV-2 virus (previously 2019-nCoV) and develop diagnostic tests, treatments and vaccines. Crucial questions about this virus need to be answered so quick and reliable research tools matter now more than ever. We at BIOKÉ support the fight against COVID-19 by offering a range of high quality products for virus research, from viral purification kits to qPCR plates, together with our reliable technical support.
LEIDEN, December 3, 2019 - Please be aware that our European office will be closed from Wednesday December 25, 2019 up and until January 2, 2020. We will reopen for business again on Thursday January 2, 2020. Check the last order date to make sure you have your products in time!
LEIDEN, June 7, 2019 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), announced that it has signed a distribution agreement with Parallex BioAssays, an innovative biotech company that develops breakthrough antibody microarrays for the biomedical and food industries, to distribute the SnapChipTM Cellular Signaling Series in the Netherlands, Belgium and Luxembourg (collectively, the “BeNeLux”) market.
LEIDEN June 3, 2019 - The European Society for Human Genetics (ESHG) is organizing its annual conference in Gothenburg, Sweden, from June 15 – 18, 2019. More than 3.500 global researchers and clinicians will attend this European meeting. At the ESHG conference you will find the latest developments in the field of human genetics.
LEIDEN April 23, 2019 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe) announced that they have signed an agreement with GE Healthcare allowing BIOKÉ to distribute the GE's Amersham Typhoon Gel and Blot imaging systems in the BeNeLux countries (Netherlands, Belgium, Luxembourg), effective immediately.
ATLANTA, GA (PRWEB) - March 30, 2019 – Today, at the American Association of Cancer Research conference, Cell Press, a leading publisher of over 40 primary research and review journals, and Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, are excited to announce a new educational resource that will make it easier for biology students and researchers to navigate their careers, get published, and strengthen their laboratory skills to enable experimental success. The new resource is entitled Cell Mentor™.
Danvers, MA – March 7, 2019 - Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, today announced they have been named the winner of the 2019 CiteAb awards for Life Science Reagent Supplier of the Year and Antibody Validation Initiative, recognizing the company’s efforts in proactively engaging in a number of validation initiatives designed to improve the quality and quantity of data available to researchers.
LEIDEN, January 14, 2019 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), announced it has signed a distribution agreement with OLS OMNI Life Science GmbH & Co KG, a leading manufacturer and distributor of cell culture and cell assay systems for Life Science research and drug development, to distribute OLS' CERO benchtop 3D incubator and bioreactor and OLS' CASY Cell Counter and Analyzer in the Netherlands, Belgium and Luxembourg.
LEIDEN, November 22, 2018 - Our office will be closed from Monday, December 24, 2018 until Tuesday January 1, 2019. Our office will reopen for business again on Wednesday, January 2, 2019. Check the last order date to make sure you have your products in time!
SAN DIEGO June 27, 2018 - With the goal of improving the antimicrobial drug discovery process, scientists in Finland will employ xCELLigence technology to identify compounds active against E. coli biofilms
IPSWICH, MA (July 10, 2018) — New England Biolabs (NEB®) today announced the launch of the NEBNext Direct Custom Ready Panels. The new panels — coupled with the proprietary NEBNext Direct target enrichment technology — enable the rapid development and deployment of a customized target enrichment panel by allowing users to select from an extensive library of genes to produce sequencing data with high specificity and coverage uniformity.
IPSWICH, Mass., June 11, 2018 /PRNewswire/ -- Some of today's most exciting molecular biology engineering — including the creation of customized CRISPR/Cas9 and TALEN constructs for genome editing — are led by synthetic biologists. These scientists are using methods such as Golden Gate Assembly. This molecular cloning technique uses a combination of Type IIS restriction enzymes and DNA ligase to assemble multiple DNA fragments simultaneously in a rapid "one-pot" reaction.
LEIDEN June 13, 2018 - The European Society for Human Genetics (ESHG) is organizing its annual conference in Milan, Italy, from June 16 – 19, 2018. More than 2.500 global researchers and clinicians will attend this European meeting. At the ESHG conference you will find the latest developments in the field of human genetics.
IPSWICH, Mass., June 14, 2018 /PRNewswire/ -- New England Biolabs (NEB®) today announced the release of the NEBNext® Single Cell/Low Input RNA Library Prep Kit for Illumina®. This new kit incorporates an optimized template switching protocol— as well as NEB's Ultra™ II FS enzymatic DNA fragmentation technology— to produce full-length transcript sequence-ready libraries from single cells and ultra-low input RNA.
SAN DIEGO May 3, 2018 - Continuing its track record as an innovator in in flow cytometry, today, ACEA Biosciences released the most advanced benchtop flow cytometer on the market. The NovoCyte Quanteon flow cytometer builds upon its wildly successful predecessor, the NovoCyte, to provide an expanded set of capabilities that easily accommodates the large, multi-color panels found in today’s highly progressive flow cytometry laboratories. Scientists now have the flexibility to choose from 25 fluorescent channels utilizing four lasers (405, 488, 561, and 637nm) with 25 independent silicon photomultiplier (SiPM) detectors....
DANVERS, MA (PRWEB) – April 5, 2018, Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has opened a new office in Shanghai China to support the rapidly expanding China life science market and the growth of the CST business in the country.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCARs) involving keratinocyte apoptosis and detachment of the epidermis. Current treatments, which include the use of corticosteroids, are controversial in their effectiveness. Numerous studies have demonstrated that the mechanism of SJS-TEN involves effector cytotoxic T lymphocytes (CTLs). In addition, treatment with anti–TNF-α biologic agents appears to be beneficial in patients with TEN and TEN-like acute cutaneous lupus erythematosus. However a randomized, systemic trial had not yet been run.
FEBRUARY 15, 2018, DANVERS, MA – Cell Signaling Technology, Inc. (CST), a leading provider of antibodies, kits, and services, is honored with the 2018 CiteAb Award for “Antibody Company of the Year” and “Antibody Company Succeeding in Cancer Biology.” CST was also highly commended for the “Chemical Probes Supplier to Watch” and “Antibody Company with Sustained Success in China.” The CiteAb Antibody Awards aim to celebrate the very best suppliers, reagents, and individuals in the research antibody sector, recognizing the efforts that are made to progress science.
DECEMBER 8, 2017 - By expressing a secreted form of an EpCAM-specific BiTE molecule in the cancer cells it infects, a novel oncolytic virus both kills cells directly and induces a robust cytotoxic T cell response.
DECEMBER 14, 2017 - Using xCELLigence Real-Time Cell Analysis (RTCA), Sanofi Pasteur scientists have developed an assay for accurate viral titer determination that is 5-times less labor intensive and 3.5-times cheaper than conventional methods
SAN DIEGO December 12, 2017 - Using xCELLigence Real-Time Cell Analysis (RTCA) scientists at Genentech have developed an automated and high throughput assay for studying the molecular determinants of bronchoconstriction/dilation. Read more.
SAN DIEGO NOVEMBER 30, 2017 - ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership to provide comprehensive solutions for cardiac drug discovery and cardiac safety assessment. This multifaceted partnership will include the joint development of applications, co-marketing, and commercial activities.
Ipswich, MA, USA (November 7, 2017) — New England Biolabs (NEB®) today announced the release of the NEBNext Ultra II FS DNA Library Prep Kit for next generation sequencing (NGS). This new kit employs a novel enzymatic fragmentation system that combines fragmentation, end repair and dA-tailing in a single tube, and utilizes a single protocol regardless of input amount or GC content.
Xiamen, China – November 2, 2017 - Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has announced that Jay Dong, General Manager of its China operations, has been elected Co-President of the Chinese Society for Cell Biology’s Academia-Industry Consortium for Innovation and Entrepreneurship. This consortium was formed to support translation of basic research into translational medicine. Dong was inaugurated by Dr. Yeguang Chen, President of Chinese Society for Cell Biology (CSCB) at CSCB 2018 Conference in Xiamen, China.
SAN DIEGO, OCTOBER 20, 2017 - Employing the xCELLigence® technology from ACEA Biosciences, a team of Spanish scientists have developed a real-time assay for screening anti-biofilm treatments and quantifying their efficacy. Biofilms are surface-attached communities of bacterial or fungal cells that are enmeshed in an extensive extracellular matrix which makes them more resistant to both antibiotics and the immune system. With biofilms estimated to be responsible for >60% of microbial infections, and 80% of chronic infections in humans, finding ways to disrupt established biofilms is of critical importance. In recent years there has been a growing interest in exploiting bacteriophages, or the lytic proteins that they encode, to treat biofilms.
Leiden, The Netherlands, August 21, 2017 - Pluriomics and ACEA Biosciences (ACEA) today announced a cooperation to advance together cardiac drug discovery and expand Pluriomics service portfolio. This cooperation will give Pluriomics access to ACEA xCELLigence® Real-Time Cell Analysis (RTCA) CardioECR instrument which enables them to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology.
CHELMSFORD, Mass., October 5th, 2017 – Brooks Automation, Inc. announced today that it has acquired 4titude, Ltd., a privately-held manufacturer of scientific consumables for biological sample materials used in a variety of genomic and DNA analytical applications. Based in Surrey, England and over 12 years of operations and approximately 85 employees, 4titude is widely recognized for its innovative range of Polymerase Chain Reaction (PCR) plates, seals and related bench-top instrumentation. 4titude has delivered consistent growth over the last 5 years with sales and distribution globally to 1200 customers in 50 different countries.
Danvers, MA – September 5, 2017 – Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has announced changes in part of its European operations. On January 1st, 2018, CST will now deal directly with its customers in Germany and Austria.
August 18, 2017 State College PA - SoftGenetics announced that it has purchased the assets of Mitotyping Technologies, originally founded by Terry Melton, from Health Network laboratories of Allentown PA. The addition of Mitotyping Technologies furthers SoftGenetics goal of becoming a dominant source to the world-wide DNA forensic community, which in addition to Mitotyping Technologies includes software tools for STR Analysis, Mitochondrial and STR analysis of nextgeneration data and the soon to be released MaSTR™ continuous mixture probabilistic software.
IPSWICH, MA, USA (August 1, 2017) — Detecting a specific DNA sequence outside of the laboratory, without bulky equipment or even electricity, may seem unlikely. However, astronauts aboard the International Space Station (ISS) did just that using a technique developed by New England Biolabs (NEB).
IPSWICH, Mass. and HEIDELBERG, Germany, July 25, 2017 /PRNewswire/ -- The EMBL Advanced Training Centre (ATC) welcomes New England Biolabs (NEB®) as its newest member of their Corporate Partnership Programme. Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life sciences industry, NEB is a recognized world leader in the discovery, development and commercialization of recombinant and native enzymes for genomic research.
Ipswich, MA, USA and Norwich, UK (June 7th, 2017) – In its mission to tackle global challenges through life science research, the Earlham Institute (Norwich, UK) faces unique problems raised through the sheer breadth of biological samples that it works with. Samples that the institute processes can come from any number of species of plant, animal, or microbial organism.
SAN DIEGO JUNE 14, 2017 - ACEA Biosciences today announced the completion of its Phase 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor, which is in development for the treatment of B cell-related autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. Fifty-six (56) healthy subjects participated in the double-blind, placebo-controlled trial, which......
IPSWICH, Mass., May 30, 2017 - The kits are compatible with poly(A) mRNA isolation and ribosomal RNA (rRNA) depletion, and libraries can be constructed from a substantially broader input range (5 ng to 1 µg of total RNA) at high yields. New Ultra II technology addresses lower input amounts and challenging sample types for Illumina® next generation sequencing systems.
ROSWELL, Ga. June 13, 2017 – As a life sciences company, Cell Signaling Technology (CST) uses about 200,000 pairs of gloves each year. But that glove waste no longer goes into a landfill. CST diverts it through an innovative program that has enabled the company to recycle more than 4,400 pounds of gloves, which are then turned into flower pots, lawn furniture, and other products.
SAN DIEGO, May 3, 2017 - The NovoCyte system with its updated software and firmware provides broader versatility and flexibility with its multi-option optical configuration capabilities. This update also brings the release of the new ACEA NovoCyte 3005 3 lasers system that provides up to 17 parameters including forward and side scatter.
LEIDEN, April 3, 2017 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), and Bethyl Laboratories, Inc. announced that they have signed an agreement allowing BIOKÉ to exclusively distribute Bethyl’s products in the BeNeLux countries, effective immediately.
LEIDEN, March 22, 2017 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe), and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s xCELLigence® Cell Analyzer in the BeNeLux countries, effective immediately.
February 10, 2017, Danvers, MA — Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for “PTM Antibody Company of the Year” and for a third year in a row with the award for “Researchers’ Choice.” CST was also a close runner-up for the “Antibody Company of the Year” award. The CiteAb Antibody Awards aim to celebrate the very best suppliers, reagents, and individuals in the research antibody sector, recognizing the efforts that are made to progress science.
January 26, 2017, State College PA - SoftGenetics announced the availability of its new GeneMarkerHTS software for analysis of the Mitochondrial Genome for Forensic and Clinical Research applications from High Throughput Sequencing systems. GeneMarkerHTS is believed to be the first commercially available software developed exclusively for analysis of NGS Mitochondrial sequencing, is applicable in many cases including mass disaster, missing person, as well as clinical disease research and forensic anthropology applications.
January 19, 2017, State College PA - SoftGenetics announced the availability of the latest version of ChimerMarker software. ChimerMarker software, automated chimerism analysis software, integrates speed and accuracy with a biologist‐friendly interface. The software can be used to monitor chimerism levels in both allogeneic and autologous stem cells transplant or hematopoietic stem ...
DANVERS, Mass - November 21, 2016 – Honored as a life science leader at the 2016 Life Science Industry Awards (LSIA), Cell Signaling Technology (CST), a worldwide provider of antibodies, received Best Customer Service for its outstanding commitment to antibody quality and customer satisfaction. The LSIA recognizes .......
LEIDEN, October 24, 2016 - BIOKÉ, a Cell Signaling Technology Europe (CST Europe) company, and ACEA Biosciences, Inc., a high performance cell analysis platforms manufacturer, announced their partnership to exclusively distribute ACEA’s NovoCyte™ Flow Cytometer in the BeNeLux countries, effective immediately.
June 13, 2016 - Cell Signaling Technology (CST), CST, a worldwide provider of antibodies, is providing four high school juniors from Boston North Shore communities—Gloucester, Lynn, Peabody and Salem—with $10,000 each to pursue a college education in a science-related program.
April 12, 2016 - Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, released four new monoclonal antibodies relevant to the rapidly growing fields of immunometabolism and tumor immunology.
NOVEMBER 3, 2015, NATIONAL HARBOR, MD (US BUSINESS WIRE) Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD November 4-8th, 2015.